Payment overview · 2025
General Payments
$857.73
35 reported records · 12 companies
Healthcare provider profile · identity verified
Michael Park, D.O
Allopathic & Osteopathic Physicians|General Practice · ATLANTA, GA · NPI 1285997700
Verified facts
What the public records show
CMS Open Payments records show Michael Park, D.O received $857.73 in general payments during 2025 across 35 reported records.
Gilead Sciences, Inc. accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $157.58 | 18.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.77 | 16.4% | 7 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $126.18 | 14.7% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $123.95 | 14.4% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.63 | 10.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.38 | 6.0% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $43.49 | 5.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $42.54 | 5.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.04 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.22 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.04 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.91 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $857.73 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $140.77 | 7 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $126.18 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $123.95 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.51 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.51 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $51.38 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $51.38 | 3 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $43.49 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $42.54 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 658 | 221 |
| Atorvastatin Calcium | Atorvastatin Calcium | 649 | 194 |
| Losartan Potassium | Losartan Potassium | 414 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 84 |
| Lisinopril | Lisinopril | 260 | 86 |
| Omeprazole | Omeprazole | 208 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 62 |
| Metformin Hcl | Metformin Hcl | 161 | 52 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 156 | 27 |
| Sertraline Hcl | Sertraline Hcl | 142 | 42 |
| Gabapentin | Gabapentin | 138 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 39 |
| Trazodone Hcl | Trazodone Hcl | 116 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 27 |
| Bupropion Xl | Bupropion Hcl | 93 | 29 |
| Alprazolam | Alprazolam | 92 | 33 |
| Simvastatin | Simvastatin | 89 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 26 |
| Allopurinol | Allopurinol | 77 | 26 |
| Furosemide | Furosemide | 77 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 24 |
| Azithromycin | Azithromycin | 71 | 65 |
| Prednisone | Prednisone | 70 | 54 |
| Carvedilol | Carvedilol | 66 | 28 |
| Montelukast Sodium | Montelukast Sodium | 65 | 23 |
| Tramadol Hcl | Tramadol Hcl | 65 | 19 |
| Glipizide | Glipizide | 62 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 20 |
| Ozempic | Semaglutide | 59 | 15 |
| Potassium Chloride | Potassium Chloride | 59 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 48 |
| Eliquis | Apixaban | 55 | 21 |
| Metformin Hcl Er | Metformin Hcl | 55 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 13 |
| Diazepam | Diazepam | 45 | suppressed |
| Valsartan | Valsartan | 44 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 14 |
| Ezetimibe | Ezetimibe | 43 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 14 |
| Valacyclovir | Valacyclovir Hcl | 39 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Ibuprofen | Ibuprofen | 38 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Carisoprodol | Carisoprodol | 36 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 11 |
| Meclizine Hcl | Meclizine Hcl | 32 | 16 |
| Meloxicam | Meloxicam | 32 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 27 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 14 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Famotidine | Famotidine | 27 | 11 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 12 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 17 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 12 |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 15 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Mupirocin | Mupirocin | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $857.73 · 35 records | Gilead Sciences, Inc. | AREXVY, EVENITY, General - Pain Management, INSPIRE, LEQVIO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, SHINGRIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error